Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Dr. Agarwal's Health Care Limited (AGARWALEYE.NS)
Chennai, IN
Dr. Agarwal's Health Care Limited manages a chain of eye hospitals both within India and abroad. The company delivers a comprehensive range of ophthalmic services, including advanced surgical solutions for cataracts like small incision, phacoemulsification, robotic, and glued intraocular lens procedures. It also offers refractive surgeries designed to correct visual errors, thereby lessening or removing the necessity for glasses and contact lenses. Additional surgical specialties include treatments for retinal conditions, corneal transplantation, pinhole pupilloplasty, oculoplasty, and operations for glaucoma and pterygium. Beyond surgical interventions, the company provides professional medical consultations, in-depth diagnostic services for various eye disorders, and non-surgical therapies such as retinal laser treatment and dry eye management. Furthermore, Dr. Agarwal's Health Care Limited sells optical goods, including spectacles, lenses, contact lenses, and frames, as well as a variety of pharmaceutical products for eye care. The company was founded in 2010 and is based in Chennai, India.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.02% | +4.03% | +9.47% | +7.08% | -6.11% | -5.66% | +25.04% | +19.44% | +19.44% | +19.44% | +19.44% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 3 | +1 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%+21.6% ★ Q1'26: +22.6% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%+50.4% ★ Q1'26: +20.4% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+3.6% ★ Q1'26: +8.8% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+14.1% ★ Q1'26: +15.0% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%+6.8% ★ Q1'26: +7.6% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%+6.1% Q1'26: +3.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×1.87× Q1'26: 1.65× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2025 actual |
Mar 2026 5 Rev. Ana. 4 EPS Ana. |
Mar 2027 5 Rev. Ana. 4 EPS Ana. |
Mar 2028 5 Rev. Ana. 4 EPS Ana. |
Mar 2029 1 Rev. Ana. 2 EPS Ana. |
Mar 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
17.11B
est: 17.00B (+0.6%)
|
20.69B
20.56B – 20.82B
+21.7% YoY
|
25.21B
24.61B – 25.44B
+21.9% YoY
|
30.50B
29.18B – 31.00B
+21.0% YoY
|
36.33B
36.31B – 36.34B
+19.1% YoY
|
43.00B
41.52B – 43.56B
+18.4% YoY
|
| EBITDA |
4.99B
est: 4.98B (+0.2%)
|
6.06B
6.02B – 6.10B
+21.7% YoY
|
7.39B
7.21B – 7.45B
+21.9% YoY
|
8.93B
8.55B – 9.08B
+21.0% YoY
|
10.64B
10.64B – 10.65B
+19.1% YoY
|
12.60B
12.16B – 12.76B
+18.4% YoY
|
| EBIT |
2.69B
est: 2.75B (-2.2%)
|
3.34B
3.32B – 3.36B
+21.7% YoY
|
4.07B
3.98B – 4.11B
+21.9% YoY
|
4.93B
4.71B – 5.01B
+21.0% YoY
|
5.87B
5.87B – 5.87B
+19.1% YoY
|
6.95B
6.71B – 7.04B
+18.4% YoY
|
| Net Income |
834.60M
est: 879.55M (-5.1%)
|
1.33B
1.27B – 1.36B
+51.4% YoY
|
1.86B
1.75B – 1.91B
+39.4% YoY
|
2.66B
2.55B – 2.72B
+43.4% YoY
|
3.66B
3.63B – 3.69B
+37.5% YoY
|
4.59B
4.38B – 4.67B
+25.4% YoY
|
| SGA |
2.92B
est: 1.77B (+64.9%)
|
2.16B
2.14B – 2.17B
+21.7% YoY
|
2.63B
2.57B – 2.65B
+21.9% YoY
|
3.18B
3.04B – 3.23B
+21.0% YoY
|
3.79B
3.79B – 3.79B
+19.1% YoY
|
4.48B
4.33B – 4.54B
+18.4% YoY
|
| EPS |
2.80
est: 2.80 (+0.0%)
|
4.14
4.00 – 4.26
+48.0% YoY
|
5.83
5.50 – 6.00
+40.8% YoY
|
8.30
8.01 – 8.54
+42.2% YoY
|
11.49
11.39 – 11.59
+38.5% YoY
|
14.40
13.75 – 14.65
+25.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-26 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-25 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-22 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI India Small-Cap ETF SMIN | 0.11% | 806.7K | 0.74% |
| 2 | iShares MSCI Emerging Markets Small-Cap ETF EEMS | 0.03% | 112.2K | 0.72% |
| 3 | iShares MSCI EM Small Cap UCITS ETF IEMS.L | 0.02% | 70.2K | 0.74% |
| 4 | State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L | 0.02% | 110.2K | 0.55% |
| 5 | iShares MSCI EM IMI Screened UCITS ETF SEDM.L | 0.00% | 29.0K | 0.18% |
| 6 | iShares Core MSCI EM IMI UCITS ETF EIMU.L | 0.00% | 34.6K | 0.18% |
| 7 | iShares Core MSCI EM IMI UCITS ETF EIMI.L | 0.00% | 844.5K | 0.18% |
| 8 | iShares Core MSCI Emerging Markets IMI Index ETF XEC.TO | 0.00% | 55.0K | 0.28% |
| 9 | iShares Core MSCI All-Country World ex Canada Index ETF XAW.TO | 0.00% | 7.0K | 0.22% |
| 10 | iShares Core Equity ETF Portfolio XEQT.TO | 0.00% | 12.0K | 0.20% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Adil Agarwal | Chief Executive Officer & Whole-Time Director | 50M | — |
| Anosh Agarwal Ophthal | Chief Operating Officer & Wholetime Director | 50M | — |
| Ashar Agarwal | Chief Business Officer | 24M | — |
| Ashvin Agarwal | Chief Clinical Officer | 8M | — |
| Thanikainathan Arumugam | Vice President of Corporate Affairs, Company Secretary & Compliance Officer | 7M | male |
| Yashwanth Venkat | Chief Financial Officer | 3M | male |
| Rahul Agarwal | Chief Operating Officer- Hospital Operations | — | male |
| Vandana Jain | Chief Strategy Officer | — | — |
| Aashna Dharia | Head of Investor Relations | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AGARWALEYE.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
